Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Diego Signorelli
Observed names:
D. Signorelli,
Signorelli, Diego
Institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Observed institutions:
Università Cattolica del Sacro Cuore,
Rush University Medical Center,
Agostino Gemelli University Polyclinic,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
Fatebenefratelli Hospital,
Fondazione IRCCS Istituto Nazionale dei Tumori
show all 6
ORCID:
0000-0001-5507-7820
Observed ORCID:
0000-0001-5507-7820
OpenAlex ID:
A5011289747
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
2018
·
Giuseppe Lo Russo
, Massimo Moro
, et al.
·
Clinical Cancer Research
·
422
PDF
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
2024
·
Jonathan D Spicer
, Marina C Garassino
, et al.
·
The Lancet
·
409
PDF
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2020
·
Fausto Petrelli
, Diego Signorelli
, et al.
·
Cancers
·
317
PDF
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
2019
·
Giovanni Fucà
, Giulia Galli
, et al.
·
ESMO Open
·
221
PDF
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
2019
·
Lorenza Landi
, Federica D’Incà
, et al.
·
Journal for ImmunoTherapy of Cancer
·
176
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
2021
·
Alessio Cortellini
, Massimo Di Maio
, et al.
·
Journal for ImmunoTherapy of Cancer
·
171
PDF
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
2019
·
C. Proto
, R. Ferrara
, et al.
·
Cancer Treatment Reviews
·
164
PDF
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
2022
·
Giuseppe Viscardi
, Antonino C. Tralongo
, et al.
·
European Journal of Cancer
·
162
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
2020
·
Alessio Cortellini
, Biagio Ricciuti
, et al.
·
Journal for ImmunoTherapy of Cancer
·
109
PDF
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
2020
·
Alessio Cortellini
, Marcello Tiseo
, et al.
·
Cancer Immunology Immunotherapy
·
104
PDF
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
2021
·
Corrado Campochiaro
, Nicola Farina
, et al.
·
European Journal of Internal Medicine
·
99
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020
·
Alessio Cortellini
, Alex Friedlaender
, et al.
·
Clinical Lung Cancer
·
93
PDF
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
2019
·
Mattia Boeri
, Massimo Milione
, et al.
·
Clinical Cancer Research
·
89
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
2019
·
Arsela Prelaj
, Roberto Ferrara
, et al.
·
Cancers
·
84
PDF
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
2019
·
Francesco Grossi
, Carlo Genova
, et al.
·
European Journal of Cancer
·
79
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer
2019
·
Giulia Galli
, Tiziana Triulzi
, et al.
·
Lung Cancer
·
76
Cognitive impairment and chemotherapy: a brief overview
2017
·
Milena Vitali
, Carla Ida Ripamonti
, et al.
·
Critical Reviews in Oncology/Hematology
·
75
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022
·
L. Cantini
, G. Mentrasti
, et al.
·
ESMO Open
·
73
PDF
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
2019
·
Giulia Galli
, Alessandro De Toma
, et al.
·
Lung Cancer
·
73
Treatment of lung large cell neuroendocrine carcinoma
2016
·
Giuseppe Lo Russo
, Sara Pusceddu
, et al.
·
Tumor Biology
·
68
PDF
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021
·
G.L. Banna
, A. Cortellini
, et al.
·
ESMO Open
·
66
PDF
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
2019
·
Federico Nichetti
, Francesca Ligorio
, et al.
·
Cancers
·
66
PDF
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
2020
·
Giuseppe Luigi Banna
, Diego Signorelli
, et al.
·
Translational Lung Cancer Research
·
64
PDF
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
2022
·
Mariona Riudavets
, Edouard Auclin
, et al.
·
European Journal of Cancer
·
63
PDF
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
2021
·
Arsela Prelaj
, Achille Bottiglieri
, et al.
·
European Journal of Cancer
·
59
Show more works
View as search
Works count:
235
Citation count:
5,266
H-index:
40
I10-index:
81
Year
Topic
Type